Ozempic Users Are Skimping Out on Exercise, Study Finds
New research indicates that patients taking GLP-1 weight loss drugs are reducing their physical activity levels.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
A recent study finds that physical activity declines among individuals using GLP-1 medications for obesity. Coverage from Healio, Medical Xpress, and Neuroscience News highlights that patients taking these drugs are moving less, with ScienceDaily reporting similar trends for those on weight loss medications like Ozempic.
The Times and Yahoo Creators focus on the implications of this reduced movement, specifically the potential for muscle loss. Morningstar and The Times explore strategies for training and preserving muscle mass while using these treatments, though coverage does not yet specify the exact mechanisms driving the behavior change.
Case Western Reserve University features expert analysis from Ian Neeland regarding the health effects of GLP-1 drugs. Healthline examines the reasons users are less likely to exercise.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 134d ago.
Quick answers
What does the new study reveal?
The study finds that physical activity and spontaneous movement decline in patients after they start GLP-1 obesity treatments.
What is the primary health concern noted?
Coverage emphasizes the risk of muscle loss associated with reduced exercise while taking GLP-1 weight loss drugs.
Are there solutions being discussed?
Outlets like The Times and Morningstar provide guidance on how to train and lose weight without losing muscle during treatment.
Coverage (14)
- Exercise declined in patients with obesity after starting a GLP-1 Healio · 137d ago
- The GLP-1 workout: how to train if you’re on fat jabs The Times · 137d ago
- Physical activity declines after starting GLP-1 obesity treatments News-Medical · 137d ago
- People taking GLP-1 weight loss drugs like Ozempic started moving less ScienceDaily · 137d ago
- People taking GLP-1 weight loss drugs like Ozempic started moving less ScienceDaily · 137d ago
- Physical Activity Declines Among Individuals Using GLP-1 Medications, Study Finds Bioengineer.org · 137d ago
- GLP-1 Therapies Silence Spontaneous Physical Activity Neuroscience News · 137d ago
- GLP-1 Weight Loss Can Mean Muscle Loss Yahoo Creators · 137d ago
- Study finds exercise decreases among people taking GLP-1 medication Medical Xpress · 137d ago
- The GLP-1 Era: How To Lose Weight Without Losing Muscle Morningstar · 137d ago
- Medicine's Ian Neeland explores the health effects of GLP-1 drugs Case Western Reserve University · 137d ago
- The 20-minute Ozempic workout The Times · 137d ago
- Ozempic, Wegovy: Why People Using GLP-1s Are Less Likely to Exercise Healthline · 137d ago
- Ozempic Users Are Skimping Out on Exercise, Study Finds Gizmodo · 137d ago
Topics
Related trends
Retatrutide beats Ozempic on weight loss, blood sugar control, study says
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
Eli Lilly reports that its new drug, retatrutide, achieved more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial.
GLP-1 drug coverage is being dropped by employer plans: What to know about 2027 weight-loss options
Employer health plans are increasingly dropping GLP-1 weight-loss drug coverage as cash prices soar and 2027 options remain uncertain.
Women On GLP-1s Are Revealing The Side Effects And Experiences No One Told Them About
Women and patients using GLP-1 medications are sharing personal experiences regarding the gap between treatment expectations and the reality of side effects.
5 Menopause Research Updates That Could Shape Care
New research suggests a synergy between hormone therapy and GLP-1 weight-loss medications for women navigating menopause.
Triple-action weekly weight-loss drug reduces sleep apnea in two late-stage trials
An investigational triple-action weekly weight-loss drug significantly reduces obstructive sleep apnea severity in late-stage clinical trials.